Rite Aid Corporation (RAD)
Chart Events
Performance Outlook
| Previous Close | 6.98 |
| Open | 7.13 |
| Bid | 7.34 x 800 |
| Ask | 7.35 x 1000 |
| Day's Range | 7.13 - 7.49 |
| 52 Week Range | 4.68 - 19.22 |
| Volume | |
| Avg. Volume | 4,347,508 |
| Market Cap | 406.852M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.12 |
| Earnings Date | Apr 13, 2022 - Apr 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 14, 1999 |
| 1y Target Est | 3.00 |
- Motley Fool
Zoom Video Communications: Bull vs. Bear
Why Rite Aid's (NYSE: RAD) stock pop and raised guidance still aren't enough to get him interested in buying shares. Additionally, with shares down nearly 70% over the past year, is Zoom Video Communications (NASDAQ: ZM) a screaming buy or past its prime? To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
- Yahoo Finance Video
Walgreens earnings top estimates, sales drop 4.2%
Yahoo Finance Live anchors discuss third-quarter earnings for Walgreens.
- Business Wire
Elixir Launches Specialty Generic Enhancement that Leads to Thousands in Annual Savings for Plan Sponsors and Members
PHILADELPHIA, June 30, 2022--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.
